Authors
Latest:
Dr Dotan on Treating Geriatric Patients With Gastroesophageal CancerEfrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.
Latest:
Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Latest:
Dr. O’Malley on the Utility of Chemoimmunotherapy in Ovarian CancerDavid M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.
Latest:
Dr Minchom on the Safety of Subcutaneous Amivantamab in Advanced Solid TumorsAnna R. Minchom MD, BCh, MB, MRCP, discusses the safety and recommended phase 2 doses of subcutaneous amivantamab-vmjw for patients with advanced solid tumors in the phase 1b PALOMA trial.
Latest:
Dr Tarantino on the Potential Significance of SGN-B7H4V in Breast CancerPaolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.
Latest:
A Prayer for a More Equitable FutureRussell J. Ledet, PhD, discusses being a Black man in the field of oncology.
Latest:
The Mullin SistersA breast surgical oncology fellow tells the story of how 3 women in his family helped shape his career and provide a purpose for his passion.
Latest:
Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLCJaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.
Latest:
Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C MutationJayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.
Latest:
Taking Back Our Empathy: Reflections on a New Model of Medical EducationBharat Sanders sheds light on how patient-centered medical education put him behind the eyes of the patient and fundamentally changed the way he practices medicine.
Latest:
Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in MyelomaMonalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.
Latest:
Exciting Treatment Opportunities in mCRCClosing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.
Latest:
Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRCAmanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.
Latest:
Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple MyelomaAmandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.
Latest:
Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCLAriel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.
Latest:
Extending the Frontiers of Checkpoint Inhibition in Merkel Cell CarcinomaIn the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.
Latest:
Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic CancerMatthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.
Latest:
Dr Gehrig on the Use of Genetic Testing in Endometrial CancerPaola Gehrig, MD, discusses the optimal use and timing of genetic testing in endometrial cancer.
Latest:
Dr. Narkhede on Siltuximab for CRS and ICANS in Hematologic MalignanciesMayur Narkhede, MD, discusses findings from a pre-planned interim analysis of a phase 2 trial investigating siltuximab for the treatment of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome related to CAR T-cell therapy in adult patients with hematologic malignancies.
Latest:
Unanswered Questions in HER2+ Breast CancerConsiderations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.
Latest:
Dr. Lin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCLRichard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Latest:
Dr Porter on the Potential Role for Taletrectinib in ROS1+ NSCLCJason Porter, MD, discusses the potential role of the next-generation TKI taletrectinib in patients with ROS1-positive non–small cell lung cancer, according to data from the phase 2 TRUST-II trial.
Latest:
Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate CancerVinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.
Latest:
Dr. Sandhu on Findings with Niraparib in Metastatic Prostate CancerShahneen Sandhu, MD, discusses findings with niraparib in metastatic prostate cancer from the phase 3 MAGNITUDE trial.
Latest:
Dr. Roback on Subsequent Treatment Following Ibrutinib Discontinuation in CLLTadeusz Robak, MD, PhD, discusses subsequent treatment after discontinuation of ibrutinib on the phase 3 RESONATE-2 trial in patients with chronic lymphocytic leukemia.
Latest:
Assessing the Promise of AI in Oncology: Looking to the FutureIn this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.
Latest:
Dr. Ward on the Benefits of Delaying Salvage Therapy in Prostate CancerMatthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.
